Blue Jet Healthcare Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹235Cr
- −30.9% YoY
- +22.4% QoQ
- Net profit
- ₹64Cr
- −41.8% YoY
- +60% QoQ
- Margin
- 30%
- −11 pp YoY
- +6 pp QoQ
Guidance rank: #28 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
PI vertical expected to be resilient with both top-line and margin sustainability; volume growth and new launches anticipated in FY27. Blue Jet Healthcare expects growth driven by improved order visibility in Pharmaceutical Intermediates (PI) and Contrast Media (CM) segments in FY27.
From Blue Jet Healthcare Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- PI vertical expected to be resilient with both top-line and margin sustainability; volume growth and new launches anticipated in FY27.
- Contrast media business forecasted to deliver double-digit growth in FY27 supported by volume growth and new product launches (both iodinated and gadolinium types).
- Inventory destocking in PI segment completed, leading to improved order visibility and confidence in surpassing previous peak sales of FY25.
- Two high-conviction lateral entry opportunities being planned with dedicated capacity at Vizag, expected to scale in 24-30 months.
- Peptide building blocks for GLP-1 programs progressing with pilot/lab supplies started; peptide end product stage in early phases.
- Artificial sweetener product under validation; commercial volumes expected post-Vizag facility commissioning.
2 more points from Blue Jet Healthcare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Blue Jet Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Vizag Greenfield Project: Planned total capex of approximately INR 1,000 crores over about 3 years. Phase 1 to develop dedicated manufacturing blocks for contrast media intermediates, high-intensity sweeteners, and pharma intermediates.
- Mahad Unit 3 Backward Integration Project: Final stages of completion; expected to start production in H2 FY27. Focused on key raw material for contrast media to strengthen supply chain and resilience.
- Other Additions: Capex of approximately INR 400 crores proposed in FY27 for Vizag, Mahad completion, and Ambernath expansions.
2 more points from Blue Jet Healthcare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Blue Jet Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has confirmed having orders in hand, especially in the pharma intermediates (PI) segment, with destocking largely completed and shipments rolling out. (Page 16)
- Subsequent to supply chain realignment, additional orders have been secured in the PI segment, boosting confidence in near-term volumes. (Page 14)
- For contrast media, the increase in revenue to INR190 crores in Q4 belongs entirely to the order book for that quarter, with normalized goods in transit. (Page 14)
2 more points from Blue Jet Healthcare Ltd's call on order book
Create a free account to keep reading this call
Blue Jet Healthcare Ltd — Quarterly revenue & net profit
Blue Jet Healthcare Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 235 | 340 | -30.9% | 192 | +22.4% |
| Operating profit (EBITDA) | 71 | 140 | -49.3% | 47 | +51.1% |
| Operating margin | 30% | 41% | -11 pp | 24% | +6 pp |
| Profit before tax | 87 | 147 | -40.8% | 54 | +61.1% |
| Net profit (PAT) | 64 | 110 | -41.8% | 40 | +60% |
| EPS (₹) | 3.71 | 6.35 | -41.6% | 2.32 | +59.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹376 Cr, net profit ₹103 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Blue Jet Health's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Blue Jet Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Blue Jet Healthcare Ltd Q4 FY26 results?
PI vertical expected to be resilient with both top-line and margin sustainability; volume growth and new launches anticipated in FY27. Blue Jet Healthcare expects growth driven by improved order visibility in Pharmaceutical Intermediates (PI) and Contrast Media (CM) segments in FY27.
What is Blue Jet Healthcare Ltd share price analysis?
Blue Jet Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 47.1 with a market cap of ₹11,063 Cr. Investors should review the full earnings analysis for detailed insights.
Is Blue Jet Healthcare Ltd planning capital expenditure?
Vizag Greenfield Project: Planned total capex of approximately INR 1,000 crores over about 3 years.
Keep Blue Jet Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
